Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 17/6/2019
SIETES contiene 92758 citas

 1 a 20 de 31 siguiente >>
Presentar resultados
Seleccionar todas
2.Enlace a cita original Cita con resumen
Mammen G, Rueda S, Roerecke M, Bonato S, Lev-Ran S, Rehm J. Association of Cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. J Clin Psychiatry 2018;79:5 de junio. [Ref.ID 102666]
3. Cita con resumen
Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. European Psychiatry 2013;28:7-20. [Ref.ID 94663]
4. Cita con resumen
Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ 2010;340:800-4. [Ref.ID 88314]
5. Cita con resumen
Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317-25. [Ref.ID 79533]
6. Cita con resumen
Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet 2006;368:1023-32. [Ref.ID 78031]
Katon WJ. Panic disorder. N Engl J Med 2006;354:2360-7. [Ref.ID 77107]
Taylor CB. Panic disorder. BMJ 2006;332:951-5. [Ref.ID 76805]
Van Ameringen M, Mancini C, Pipe B, Bennett M. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004;64:2199-220. [Ref.ID 72812]
10. Cita con resumen
Anónimo. Escitalopram. Un isomère du citalopram, sans aucun avantage thérapeutique. Prescrire 2004;24:325-8. [Ref.ID 69907]
11. Cita con resumen
Meier CR, Wilcock K, Jick SS. The risk of severe depression, pyschosis or panic attacks with prophylactic antimalarials. Drug Saf 2004;27:203-13. [Ref.ID 69313]
12. Cita con resumen
Davies SJC, Jackson PR, Ramsay L E, Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Arch Intern Med 2003;163:592-600. [Ref.ID 65458]
House A, Stark D. Anxiety in medical patients. BMJ 2002;325:207-9. [Ref.ID 62864]
Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002;62:655-703. [Ref.ID 61285]
Wessely S, Hyams KC, Bartholomew R. Psychological implications of chemical and biological weapons. BMJ 2001;323:878-9. [Ref.ID 59222]
16. Cita con resumen
Schwenk TL. Depression and panic disorder: drugs are necessary but often insufficient. Journal Watch 2001;21:9. [Ref.ID 57510]
17. Cita con resumen
Mavissakalian MR, Schmier JK, Flynn JA, Revicki D A. Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. Pharmacoeconomics 2000;18:383-91. [Ref.ID 52996]
Anónimo. Paroxetine for panic and PTSD. Scrip 2000;2576:22. [Ref.ID 52841]
19.Tiene citas relacionadas Cita con resumen
Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder. A randomized controlled trial. JAMA 2000;283:2529-36. [Ref.ID 51068]
20.Tiene citas relacionadas
Glass RM. Panic disorder - it's real and it's treatable. JAMA 2000;283:2573-4. [Ref.ID 50981]
Seleccionar todas
 1 a 20 de 31 siguiente >>